Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReDOS: Regorafenib Dose Optimization in mCRC
NCT02368886Phase 2Completed
- Sponsor
- Academic and Community Cancer Research United
- Start
- Mar 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of regorafenib in colorectal cancer (CRC) (4 arms), sponsored by Academic and Community Cancer Research United. Primary endpoint: Proportion of Patients Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3 at 8 weeks. Started Mar 2015; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02368886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02368886.